Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
